CD4+ Count–Guided Interruption of Antiretroviral Treatment

The members of the writing group (W.M. El-Sadr [cochair], Harlem Hospital Center and Columbia University, New York; J.D. Lundgren [cochair], Hvidovre University Hospital, Denmark; J.D. Neaton [cochair], University of Minnesota, Minneapolis; F. Gordin, Washington Veterans Affairs Medical Center, Washington, DC; D. Abrams, University of California, San Francisco; R.C. Arduino, University of Texas Medical School, Houston; A. Babiker, Medical Research Council, London; W. Burman, Denver Public Health Department; N. Clumeck, Centre Hospitalier Universitaire SaintPierre, Brussels; C.J. Cohen, Community Research Initiative of New England, Boston; D. Cohn, Denver Public Health Department; D. Cooper, National Centre in HIV Epidemiology and Clinical Research, Sydney; J. Darbyshire, Medical Research Council, London; S. Emery, National Centre in HIV Epidemiology and Clinical Research, Sydney; G. Fätkenheuer, University Hospital, Cologne; B. Gazzard, Medical Research Council, London; B. Grund, University of Minnesota, Minneapolis; J. Hoy, National Centre in HIV Epidemiology and Clinical Research, Melbourne; K. Klingman, National Institute of Allergy and Infectious Diseases, Bethesda, MD; M. Losso, Hospital General de Agudos J.M. Ramos Mejia, Buenos Aires; N. Marko witz, Henry Ford Hospital, Detroit; J. Neu haus, University of Minnesota, Minneapolis; A. Phillips, Royal Free Hospital School of Medicine, London; and C. Rappoport, University of California, San Fran cisco) of the SMART study assume responsibility for the overall content and integrity of the article. Address reprint requests to Dr. El-Sadr at Harlem Hospital Center, Division of Infectious Diseases, Rm. 3107, 506 Lenox Ave., New York, NY 10037, or at wme1@columbia.edu.

[1]  J. Neaton,et al.  Considerations in choice of a clinical endpoint for AIDS clinical trials. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). , 1994, Statistics in medicine.

[2]  A. Mocroft,et al.  Is there evidence for an increase in the death rate from liver-related disease in patients with HIV? , 2005, AIDS.

[3]  J. Lisziewicz,et al.  Structured treatment interruptions for the management of HIV infection. , 2001, JAMA.

[4]  P. Morlat,et al.  Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. , 2004, International journal of epidemiology.

[5]  P. Kissinger,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. , 1998, The New England journal of medicine.

[6]  V. Soriano,et al.  Liver toxicity caused by nevirapine. , 2002, AIDS.

[7]  J Darbyshire,et al.  CD4+ count-guided interruption of antiretroviral treatment. , 2006, The New England journal of medicine.

[8]  JD Lundgren,et al.  Changing patterns of mortality across Europe in patients infected with HIV-1 , 1998, The Lancet.

[9]  Alan S. Perelson,et al.  Decay characteristics of HIV-1-infected compartments during combination therapy , 1997, Nature.

[10]  Matthias Cavassini,et al.  CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial , 2006, The Lancet.

[11]  R. Byers,et al.  Trends in Diseases Reported on U.S. Death Certificates That Mentioned HIV Infection, 1987‐1999 , 2002, Journal of acquired immune deficiency syndromes.

[12]  D. Cooper,et al.  Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: acohort study , 1999, The Lancet.

[13]  J. Currier,et al.  Getting smarter--the toxicity of undertreated HIV infection. , 2006, The New England journal of medicine.

[14]  J. Bartlett.  Combination antiretroviral therapy and the risk of myocardial infarction , 2004 .

[15]  A. Mocroft,et al.  AIDS across Europe, 1994–98: the EuroSIDA study , 2000, The Lancet.

[16]  R. Hogg,et al.  To stop or not to stop: that is the question, but what is the answer? , 2002, AIDS.

[17]  J. Lisziewicz,et al.  Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy , 1999, Nature Medicine.

[18]  D. Cooper,et al.  Adverse effects of antiretroviral therapy , 2000, The Lancet.

[19]  F. Clavel,et al.  HIV Drug Resistance , 2000, The New England journal of medicine.

[20]  B. Hirschel,et al.  UvA-DARE ( Digital Academic Repository ) A prospective , randomized trial of structured treatment interruption for patients with chronic HIV type 1 infection , 2005 .

[21]  Roger Salamon,et al.  CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial , 2006, The Lancet.

[22]  J. Margolick,et al.  Virologic and immunologic values allowing safe deferral of antiretroviral therapy , 2002, AIDS.

[23]  R J Prineas,et al.  A new epidemiologic classification system for interim myocardial infarction from serial electrocardiographic changes. , 1989, The American journal of cardiology.

[24]  P. O'Brien,et al.  A multiple testing procedure for clinical trials. , 1979, Biometrics.

[25]  B. Hirschel,et al.  Highly Active Antiretroviral Therapy (HAART) Retreatment in Patients on CD4-Guided Therapy Achieved Similar Virologic Suppression Compared With Patients on Continuous HAART: The HIV Netherlands Australia Thailand Research Collaboration 001.4 Study , 2005, Journal of acquired immune deficiency syndromes.

[26]  Laurence L. George,et al.  The Statistical Analysis of Failure Time Data , 2003, Technometrics.

[27]  Mark R Wallace,et al.  Comparisons of Causes of Death and Mortality Rates Among HIV-Infected Persons: Analysis of the Pre-, Early, and Late HAART (Highly Active Antiretroviral Therapy) Eras , 2006, Journal of acquired immune deficiency syndromes.

[28]  Annapaola Callegaro,et al.  Effect of prolonged discontinuation of successful antiretroviral therapy on CD4 T cells: a controlled, prospective trial , 2004, AIDS.

[29]  P J Hannan,et al.  Prognostic associations of Minnesota Code serial electrocardiographic change classification with coronary heart disease mortality in the Multiple Risk Factor Intervention Trial. , 1997, The American journal of cardiology.

[30]  J. Sterne,et al.  The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy. , 2005, Archives of internal medicine.

[31]  G. Lüchters,et al.  Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection , 2003, The Lancet.

[32]  K. K. Lan,et al.  Discrete sequential boundaries for clinical trials , 1983 .

[33]  K. Tashima,et al.  Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[34]  O. Kirk,et al.  Cardio- and cerebrovascular events in HIV-infected persons , 2004, AIDS.

[35]  Ronald J. Prineas,et al.  The Minnesota Code Manual of Electrocardiographic Findings , 2009 .

[36]  T. Chun,et al.  Latent reservoirs of HIV: obstacles to the eradication of virus. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[37]  J H Shih,et al.  Sample size calculation for complex clinical trials with survival endpoints. , 1995, Controlled clinical trials.